期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 12, 期 8, 页码 981-992出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2014.930663
关键词
biomaterials; chitosan; crosslinking; drug delivery; gastric cancer; Helicobacter pylori; microspheres; mucoadhesion; nanoparticles; polyelectrolytes
资金
- FEDER funds through Programa Operacional Factores de Competitividade - COMPETE
- Portuguese funds through FCT - Fundacao para a Ciencia e a Tecnologia [PEst-C/SAU/LA0002/2013, NORTE-07-0124-FEDER-000005, FCOMP-01-0124-FEDER-020073 (PTDC/CTM-BPC/121149/2010), FCOMP-01-0124-FEDER-041276 (EXPL/CTM-BIO/0762/2013), SFRH/BD/89001/2012]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/89001/2012] Funding Source: FCT
Gastric infections are mainly caused by Helicobacter pylori (H. pylori), a bacterium that colonizes the gastric mucosa of over 50% of the world's population. Chronic H. pylori infection has been associated with gastric diseases such as chronic gastritis, peptic ulcer and gastric adenocarcinoma. Current eradication treatment relies on antibiotic-based therapies that are unsuccessful in approximately 20% of the patients. Chitosan, a natural and cationic polysaccharide has been investigated in the treatment of H. pylori infection. Due to its mucoadhesive properties, it has been used in the form of micro/nanoparticles, polyelectrolyte complexes or coatings as antibiotic encapsulation systems for gastric delivery, but alternative molecules may also be incorporated. It has been recently proposed that chitosan can also be used for H. pylori binding and scavenging from the host stomach due to its antimicrobial/binding properties. In this manuscript, a brief description of the use of chitosan in H. pylori treatment is reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据